Formulation Development
AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial
AzurRx BioPharma, Inc. recently announced positive interim data from the first 18 out of 20 patients in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT),….
Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab
Checkpoint Therapeutics, Inc. recently announced the completion of enrollment for the metastatic cutaneous squamous cell carcinoma (cSCC) cohort in its registration-enabling clinical trial of….
New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2….
Centogene Extends Global Parkinson’s Disease Study
Centogene N.V. recently announced it has extended the Rostock International Parkinson’s Disease (ROPAD) Study…..
Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial
Cybrexa Therapeutics recently announced the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex-exatecan), the company’s lead therapeutic candidate. The…
OncoTEX & Sterling Pharma Solutions Sign Clinical Manufacturing Agreement
OncoTEX Inc and Sterling Pharma Solutions recently announced that they had signed a clinical development agreement for the manufacture of OncoTex’s novel platinum-resistant oncology drug…
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin
Fortress Biotech, Inc. recently announced it has entered into an exclusive licensing agreement with Fuji Yakuhin Co. Ltd. to develop Dotinurad in the US, UK,…
Biosight Completes Enrollment in Phase 2b Study for First-Line Acute Myeloid Leukemia Therapy
Biosight Ltd. recently announced it has completed enrollment in the company’s ongoing Phase 2b trial evaluating aspacytarabine (BST-236) as a single-agent first-line acute myeloid leukemia…
Altimmune Announces New Preclinical Data for AdCOVID Demonstrating Sterilizing Immunity After a Single Intranasal Dose
Altimmune, Inc. recently announced positive results from a preclinical study of AdCOVID in a SARS-CoV-2 challenge model of infection. In this study, a single intranasal…
Proveris Laboratories Announces Expanded Services for Spray & Aerosol Characterization of Unit-Dose Nasal Drugs
Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, recently announced the expansion of contract…
New Opportunities for Oral Sustained Release Formulations With Polyvinyl Alcohol
Achieving the appropriate release kinetics for an active pharmaceutical ingredient (API) is essential to ensure success of the therapeutic. For example, for sustained release…
Celanese Live Webinar: Engineering Drug Delivery to Improve Therapeutic Outcomes
Celanese and ThermoFisher Scientific have partnered together to present the value of the VitalDose® EVA drug delivery platform and manufacturing through Hot Melt Extrusion (HME) on September 9, 2021.
Nemera’s Preservative-Free Multi-Dose Eyedropper Approved in Brazil for Aché’s NSAIDs & Dry Eye Formulations
Nemera is excited to announce that its multidose eye dropper Novelia has been approved by ANVISA for the preservative-free formulations CLILON [1] (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug….
Vectura & Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19
Vectura Group plc and Inspira Pharmaceuticals Limited recently announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the potential treatment of….
Takara Bio Europe AB & PanCryos Announce Licensing Agreement to Enable Development of Cell-Based Therapy for Diabetes
Takara Bio Europe AB (TBEAB) and PanCryos recently announce they have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines…..
Catalent Acquires Additional Facility at its Gosselies, Belgium, Campus for Commercial-Scale Plasmid DNA Manufacturing
Catalent and Promethera Biosciences recently announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its….
FORMULATION FORUM - A Quick Approach for Evaluation of Drug-Excipient Compatibility: Case of Acetylsalicylic Acid
In this study, the authors monitor acetylsalicylic acid (ASA) hydrolysis in different formulations using UPLC and TAM with the objective of comparing these methods for agreement, speed, and efficiency in predicting drug stability. In parallel, they assess the impact of the excipient choices on the stability of the ASA.
The FDA Expands Collaboration With CN Bio to Investigate Lung-on-a-Chip Model for Inhaled Drug Evaluation Applications
CN Bio recently announced the US FDA has extended its research collaboration for an additional 3 years. The scope of the research carried out with…
Scipher Applies Spectra Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies
Scipher Medicine recently announced the launch of Scipher Therapeutics, focused on discovering new targets and drugs for patients not responding to approved therapies in the…
Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE 327 Against All Six ESKAPE Pathogens
Recce Pharmaceuticals Ltd recently announced announce RECCE 327 (R327) has demonstrated bactericidal activity against all six antibiotic resistant ESKAPE pathogens, including drug-resistant mutations (superbugs) as…
